Anti-CD22 (Pinatuzumab)-Mc-VC-PABC-MMAE ADC

TypeName: Business Offer
Category:
Country: United States
Summary: This ADC product is comprised of a Pinatuzumab conjugated via a Mc-VC-PABC linker to a MMAE. The MMAE is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MMAE binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death. http://www.creative-biolabs.com/adc/target-cd22-10.htm
Description: [RequestDescription]
OfferId: 2555
Name:Creative Biolabs
Telphone:
Categories